The global Nucleic Acid-based Therapeutics market size was valued at US$ 513.5 million in 2023. With growing demand in downstream market, the Nucleic Acid-based Therapeutics is forecast to a readjusted size of US$ 677.7 million by 2030 with a CAGR of 4.0% during review period.
The research report highlights the growth potential of the global Nucleic Acid-based Therapeutics market. Nucleic Acid-based Therapeutics are expected to show stable growth in the future market. However, product differentiation, reducing costs, and supply chain optimization remain crucial for the widespread adoption of Nucleic Acid-based Therapeutics. Market players need to invest in research and development, forge strategic partnerships, and align their offerings with evolving consumer preferences to capitalize on the immense opportunities presented by the Nucleic Acid-based Therapeutics market.
Gene therapy is a technique for correcting defective genes responsible for disease development. Nucleic acid-based molecules (deoxyribonucleic acid, complementary deoxyribonucleic acid, complete genes, ribonucleic acid, and oligonucleotides) are utilized as research tools within the broad borders of gene therapy and the emerging field of molecular medicine.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
Key Features:
The report on Nucleic Acid-based Therapeutics market reflects various aspects and provide valuable insights into the industry.
Market Size and Growth: The research report provide an overview of the current size and growth of the Nucleic Acid-based Therapeutics market. It may include historical data, market segmentation by Type (e.g., Anti-Sense And Anti-Gene, Short Inhibitory Sequences), and regional breakdowns.
Market Drivers and Challenges: The report can identify and analyse the factors driving the growth of the Nucleic Acid-based Therapeutics market, such as government regulations, environmental concerns, technological advancements, and changing consumer preferences. It can also highlight the challenges faced by the industry, including infrastructure limitations, range anxiety, and high upfront costs.
Competitive Landscape: The research report provides analysis of the competitive landscape within the Nucleic Acid-based Therapeutics market. It includes profiles of key players, their market share, strategies, and product offerings. The report can also highlight emerging players and their potential impact on the market.
Technological Developments: The research report can delve into the latest technological developments in the Nucleic Acid-based Therapeutics industry. This include advancements in Nucleic Acid-based Therapeutics technology, Nucleic Acid-based Therapeutics new entrants, Nucleic Acid-based Therapeutics new investment, and other innovations that are shaping the future of Nucleic Acid-based Therapeutics.
Downstream Procumbent Preference: The report can shed light on customer procumbent behaviour and adoption trends in the Nucleic Acid-based Therapeutics market. It includes factors influencing customer ' purchasing decisions, preferences for Nucleic Acid-based Therapeutics product.
Government Policies and Incentives: The research report analyse the impact of government policies and incentives on the Nucleic Acid-based Therapeutics market. This may include an assessment of regulatory frameworks, subsidies, tax incentives, and other measures aimed at promoting Nucleic Acid-based Therapeutics market. The report also evaluates the effectiveness of these policies in driving market growth.
Environmental Impact and Sustainability: The research report assess the environmental impact and sustainability aspects of the Nucleic Acid-based Therapeutics market.
Market Forecasts and Future Outlook: Based on the analysis conducted, the research report provide market forecasts and outlook for the Nucleic Acid-based Therapeutics industry. This includes projections of market size, growth rates, regional trends, and predictions on technological advancements and policy developments.
Recommendations and Opportunities: The report conclude with recommendations for industry stakeholders, policymakers, and investors. It highlights potential opportunities for market players to capitalize on emerging trends, overcome challenges, and contribute to the growth and development of the Nucleic Acid-based Therapeutics market.
Market Segmentation:
Nucleic Acid-based Therapeutics market is split by Type and by Application. For the period 2019-2030, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Segmentation by type
Anti-Sense And Anti-Gene
Short Inhibitory Sequences
Gene Transfer Therapy
Nucleoside Analogs
Ribozymes
Aptamers
Segmentation by application
Hospitals
Academic & Research Institutes
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Wave Life Sciences
Imugene
Caperna
Phylogica
Protagonist Therapeutics
Benitec Biopharma
EGEN
BioMedica
Transgene
Copernicus Therapeutics
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Nucleic Acid-based Therapeutics Market Size 2019-2030
2.1.2 Nucleic Acid-based Therapeutics Market Size CAGR by Region 2019 VS 2023 VS 2030
2.2 Nucleic Acid-based Therapeutics Segment by Type
2.2.1 Anti-Sense And Anti-Gene
2.2.2 Short Inhibitory Sequences
2.2.3 Gene Transfer Therapy
2.2.4 Nucleoside Analogs
2.2.5 Ribozymes
2.2.6 Aptamers
2.3 Nucleic Acid-based Therapeutics Market Size by Type
2.3.1 Nucleic Acid-based Therapeutics Market Size CAGR by Type (2019 VS 2023 VS 2030)
2.3.2 Global Nucleic Acid-based Therapeutics Market Size Market Share by Type (2019-2024)
2.4 Nucleic Acid-based Therapeutics Segment by Application
2.4.1 Hospitals
2.4.2 Academic & Research Institutes
2.5 Nucleic Acid-based Therapeutics Market Size by Application
2.5.1 Nucleic Acid-based Therapeutics Market Size CAGR by Application (2019 VS 2023 VS 2030)
2.5.2 Global Nucleic Acid-based Therapeutics Market Size Market Share by Application (2019-2024)
3 Nucleic Acid-based Therapeutics Market Size by Player
3.1 Nucleic Acid-based Therapeutics Market Size Market Share by Players
3.1.1 Global Nucleic Acid-based Therapeutics Revenue by Players (2019-2024)
3.1.2 Global Nucleic Acid-based Therapeutics Revenue Market Share by Players (2019-2024)
3.2 Global Nucleic Acid-based Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2022-2024)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Nucleic Acid-based Therapeutics by Regions
4.1 Nucleic Acid-based Therapeutics Market Size by Regions (2019-2024)
4.2 Americas Nucleic Acid-based Therapeutics Market Size Growth (2019-2024)
4.3 APAC Nucleic Acid-based Therapeutics Market Size Growth (2019-2024)
4.4 Europe Nucleic Acid-based Therapeutics Market Size Growth (2019-2024)
4.5 Middle East & Africa Nucleic Acid-based Therapeutics Market Size Growth (2019-2024)
5 Americas
5.1 Americas Nucleic Acid-based Therapeutics Market Size by Country (2019-2024)
5.2 Americas Nucleic Acid-based Therapeutics Market Size by Type (2019-2024)
5.3 Americas Nucleic Acid-based Therapeutics Market Size by Application (2019-2024)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Nucleic Acid-based Therapeutics Market Size by Region (2019-2024)
6.2 APAC Nucleic Acid-based Therapeutics Market Size by Type (2019-2024)
6.3 APAC Nucleic Acid-based Therapeutics Market Size by Application (2019-2024)
6.4 China
6.5 Japan
6.6 Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Nucleic Acid-based Therapeutics by Country (2019-2024)
7.2 Europe Nucleic Acid-based Therapeutics Market Size by Type (2019-2024)
7.3 Europe Nucleic Acid-based Therapeutics Market Size by Application (2019-2024)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Nucleic Acid-based Therapeutics by Region (2019-2024)
8.2 Middle East & Africa Nucleic Acid-based Therapeutics Market Size by Type (2019-2024)
8.3 Middle East & Africa Nucleic Acid-based Therapeutics Market Size by Application (2019-2024)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Nucleic Acid-based Therapeutics Market Forecast
10.1 Global Nucleic Acid-based Therapeutics Forecast by Regions (2025-2030)
10.1.1 Global Nucleic Acid-based Therapeutics Forecast by Regions (2025-2030)
10.1.2 Americas Nucleic Acid-based Therapeutics Forecast
10.1.3 APAC Nucleic Acid-based Therapeutics Forecast
10.1.4 Europe Nucleic Acid-based Therapeutics Forecast
10.1.5 Middle East & Africa Nucleic Acid-based Therapeutics Forecast
10.2 Americas Nucleic Acid-based Therapeutics Forecast by Country (2025-2030)
10.2.1 United States Nucleic Acid-based Therapeutics Market Forecast
10.2.2 Canada Nucleic Acid-based Therapeutics Market Forecast
10.2.3 Mexico Nucleic Acid-based Therapeutics Market Forecast
10.2.4 Brazil Nucleic Acid-based Therapeutics Market Forecast
10.3 APAC Nucleic Acid-based Therapeutics Forecast by Region (2025-2030)
10.3.1 China Nucleic Acid-based Therapeutics Market Forecast
10.3.2 Japan Nucleic Acid-based Therapeutics Market Forecast
10.3.3 Korea Nucleic Acid-based Therapeutics Market Forecast
10.3.4 Southeast Asia Nucleic Acid-based Therapeutics Market Forecast
10.3.5 India Nucleic Acid-based Therapeutics Market Forecast
10.3.6 Australia Nucleic Acid-based Therapeutics Market Forecast
10.4 Europe Nucleic Acid-based Therapeutics Forecast by Country (2025-2030)
10.4.1 Germany Nucleic Acid-based Therapeutics Market Forecast
10.4.2 France Nucleic Acid-based Therapeutics Market Forecast
10.4.3 UK Nucleic Acid-based Therapeutics Market Forecast
10.4.4 Italy Nucleic Acid-based Therapeutics Market Forecast
10.4.5 Russia Nucleic Acid-based Therapeutics Market Forecast
10.5 Middle East & Africa Nucleic Acid-based Therapeutics Forecast by Region (2025-2030)
10.5.1 Egypt Nucleic Acid-based Therapeutics Market Forecast
10.5.2 South Africa Nucleic Acid-based Therapeutics Market Forecast
10.5.3 Israel Nucleic Acid-based Therapeutics Market Forecast
10.5.4 Turkey Nucleic Acid-based Therapeutics Market Forecast
10.5.5 GCC Countries Nucleic Acid-based Therapeutics Market Forecast
10.6 Global Nucleic Acid-based Therapeutics Forecast by Type (2025-2030)
10.7 Global Nucleic Acid-based Therapeutics Forecast by Application (2025-2030)
11 Key Players Analysis
11.1 Wave Life Sciences
11.1.1 Wave Life Sciences Company Information
11.1.2 Wave Life Sciences Nucleic Acid-based Therapeutics Product Offered
11.1.3 Wave Life Sciences Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.1.4 Wave Life Sciences Main Business Overview
11.1.5 Wave Life Sciences Latest Developments
11.2 Imugene
11.2.1 Imugene Company Information
11.2.2 Imugene Nucleic Acid-based Therapeutics Product Offered
11.2.3 Imugene Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.2.4 Imugene Main Business Overview
11.2.5 Imugene Latest Developments
11.3 Caperna
11.3.1 Caperna Company Information
11.3.2 Caperna Nucleic Acid-based Therapeutics Product Offered
11.3.3 Caperna Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.3.4 Caperna Main Business Overview
11.3.5 Caperna Latest Developments
11.4 Phylogica
11.4.1 Phylogica Company Information
11.4.2 Phylogica Nucleic Acid-based Therapeutics Product Offered
11.4.3 Phylogica Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.4.4 Phylogica Main Business Overview
11.4.5 Phylogica Latest Developments
11.5 Protagonist Therapeutics
11.5.1 Protagonist Therapeutics Company Information
11.5.2 Protagonist Therapeutics Nucleic Acid-based Therapeutics Product Offered
11.5.3 Protagonist Therapeutics Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.5.4 Protagonist Therapeutics Main Business Overview
11.5.5 Protagonist Therapeutics Latest Developments
11.6 Benitec Biopharma
11.6.1 Benitec Biopharma Company Information
11.6.2 Benitec Biopharma Nucleic Acid-based Therapeutics Product Offered
11.6.3 Benitec Biopharma Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.6.4 Benitec Biopharma Main Business Overview
11.6.5 Benitec Biopharma Latest Developments
11.7 EGEN
11.7.1 EGEN Company Information
11.7.2 EGEN Nucleic Acid-based Therapeutics Product Offered
11.7.3 EGEN Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.7.4 EGEN Main Business Overview
11.7.5 EGEN Latest Developments
11.8 BioMedica
11.8.1 BioMedica Company Information
11.8.2 BioMedica Nucleic Acid-based Therapeutics Product Offered
11.8.3 BioMedica Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.8.4 BioMedica Main Business Overview
11.8.5 BioMedica Latest Developments
11.9 Transgene
11.9.1 Transgene Company Information
11.9.2 Transgene Nucleic Acid-based Therapeutics Product Offered
11.9.3 Transgene Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.9.4 Transgene Main Business Overview
11.9.5 Transgene Latest Developments
11.10 Copernicus Therapeutics
11.10.1 Copernicus Therapeutics Company Information
11.10.2 Copernicus Therapeutics Nucleic Acid-based Therapeutics Product Offered
11.10.3 Copernicus Therapeutics Nucleic Acid-based Therapeutics Revenue, Gross Margin and Market Share (2019-2024)
11.10.4 Copernicus Therapeutics Main Business Overview
11.10.5 Copernicus Therapeutics Latest Developments
12 Research Findings and Conclusion
听
听
*If Applicable.
